Overview

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Status:
Completed
Trial end date:
2017-07-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
Treatments:
Ribavirin
Ritonavir